Skip to main content

Table 3 Chemotherapy studies in advanced biliary tract cancer

From: A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract

Author (year)

Drug

Number of patients

Response rate (%)

Taal (1993) [32]

MMC

30

10

Patt (1996) [33]

5FU

32

34

Interferon alfa-2b

Patt (2001) [34]

Cisplatin Interferon alpha-2b

41

21

Doxorubicin

5 FU

Penz (2001) [35]

Gemcitabine

32

22

Murad (2003) [36]

Gemcitabine

26

31

5FU

  

Kornek (2001) [37]

MMC/Capecitabine vs

51

31

MMC/gemcitabine

20

Ueno (2004) [38]

S1

19

21

Alberts (2005) [39]

Gem

42

9.5

5FU

Leucovorin

Furuse (2006) [40]

Uracil-tegafur

24

12.5

Doxorubicin

Kim (2006) [41]

Gemcitabine

29

34.5

Cisplatin

Okusaka (2006) [42]

Gemcitabine

40

17.5

Park (2006) [43]

Gemcitabine

27

33.3

Cisplatin

Hong (2007) [44]

Capecitabine

32

40.6

Cisplatin

Manzione (2007) [23]

Gemcitabine

34

41

Oxaliplatin

Furuse (2008) [45]

S1

40

35

Kim (2008) [46]

S1

51

30

Cisplatin

Oh (2008) [27]

S1

15

6.7

Oxaliplatin

Furuse (2009) [47]

Uracil-tegafur

61

6.6

Doxorubicin

Kim (2009) [25]

Gemcitabine

40

15

Oxaliplatin

Sasaki (2009) [48]

S1

28

34.3

Gemcitabine

Gruenberger (2010) [30]

Cetuximab

30

63

 

Gemcitabine

 

Oxaliplatin

Gunnlaugsson (2010) [22]

Capecitabine

39

21

 

Oxaliplatin

Kanai (2010) [49]

S1

25

30.4

Gemcitabine

Karachaliou (2010) [24]

Irinotecan

28

17.9

Oxaliplatin

Chung (2011) [50]

Irinotecan

39

20.5

Gemcitabine